MeiraGTx Holdings PLC
MGTX Healthcare Biotechnology
MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024. In the quarter to June 2026, revenue grew 8,608.6%, EPS grew 466.7%, free cash flow grew 13.1% and total debt rose 28.6%, each against the same quarter a year earlier.
Follow MGTX
MeiraGTx Holdings PLC (MGTX) Altman Z-score
MeiraGTx Holdings PLC's Altman Z-score for fiscal 2025 is −4.39, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −4.39 | (0.40) |
| FY2024 | −3.99 | (1.87) |
| FY2023 | −2.11 | (0.04) |
| FY2022 | −2.07 | (5.05) |
| FY2021 | 2.98 | 1.05 |
| FY2020 | 1.93 | (0.45) |
| FY2019 | 2.38 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.13) | — | −0.15 | |
| Retained earnings / total assets | (3.34) | — | −4.68 | |
| EBIT / total assets | (0.43) | — | −1.43 | |
| Market value of equity / total liabilities | 2.56 | — | 1.53 | |
| Sales / total assets | 0.33 | — | 0.33 | |
| Altman Z-score | Distress zone | −4.39 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −14.65 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CGEM Cullinan Therapeutics, Inc. compare | 33.6× |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.7× |
| SVRA Savara Inc. compare | −3.2× |
| MNKD MannKind Corporation compare | −3.6× |
| MGTX MeiraGTx Holdings PLC | −4.4× |
| ANRO Alto Neuroscience, Inc. compare | — |
| MLTX MoonLake Immunotherapeutics compare | — |
| AKTS Aktis Oncology, Inc. compare | — |
| JBIO Jade Biosciences, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets